Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 97-101

  Lin, Gen Min ^a  

^a HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

Acute myocardial infarction; Coronary artery bypass graft surgery; Fibrinolytic therapy; Percutaneous coronary intervention; Pexelizumab

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; HEPARIN; PEXELIZUMAB; PLACEBO; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACUTE HEART INFARCTION; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HIGH RISK PATIENT; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIMARY CORONARY REVASCULARIZATION; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; MYOCARDIAL INFARCTION; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; SINGLE-CHAIN ANTIBODIES; TREATMENT OUTCOME;

EID: 83455247328     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152911798347043     Document Type: Article

References (26)

1. Yasuda, M.; Takeuchi, K.; Hiruma, M.; Iida, H, Tahara, A.; Itagane, H.; Toda, I.; Akioka, K.; Teragaki, M.; Oku H. The complement system in ischemic heart disease. Circulation, 1990, 81, 156-163.
2. Pinckard, R.N.; Olson, M.S.; Giclas, P.C.; Terry, R.; Boyer, J.T.; O'Rourke, R.A. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J. Clin. Invest., 1975, 56, 740-750.
3. Langlois, P.F.; Gawryl, M.S. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis, 1988, 70, 95-105.
4. Vakeva, A.P.; Agah, A.; Rollins, S.A.; Matis, L.A.; Li, L.; Stahl, G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation, 1998, 97, 2259-2267.
5. Rinder, C.S.; Rinder, H.M.; Smith, B.R.; Fitch, J.C.; Smith, M.J.; Tracey, J.B.; Matis, L.A.; Squinto, S.P.; Rollins, S.A. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Invest., 1995, 96, 1564-1572.
6. Fitch, J.C.; Rollins, S.; Matis, L.; Alford, B.; Aranki, S.; Collard, C.D.; Dewar, M.; Elefteriades, J.; Hines, R.; Kopf, G.; Kraker, P.; Li, L.; O'Hara, R.; Rinder, C.; Rinder, H.; Shaw, R.; Smith, B.; Stahl, G.; Shernan, S.K. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation, 1999, 100, 2499-2506.
7. Mahaffey, K.W.; Granger, C.B.; Nicolau, J.C.; Ruzyllo, W.; Weaver, W.D.; Theroux, P.; Hochman, J.S.; Filloon, T.G.; Mojcik, C.F.; Todaro, T.G.; Armstrong, P.W.; COMPLY Investigators. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation, 2003, 108, 1176-1183.
8. Granger, C.B.; Mahaffey, K.W.; Weaver, W.D.; Weaver, W.D.; Theroux, P; Hochman, J.S.; Filloon, T.G.; Rollins, S.; Todaro, T.G.; Nicolau, J.C.; Ruzyllo, W.; Armstrong, P.W.; COMMA Investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation, 2003, 108, 1184-1190.
9. Verrier, E.D.; Shernan, S.K.; Taylor, K.M.; Van de Werf, F.; Newman, M.F.; Chen, J.C.; Carrier, M.; Haverich, A.; Malloy, K.J.; Adams, P.X.; Todaro, T.G.; Mojcik, C.F.; Rollins, S.A.; Levy, J.H.; PRIMO-CABG Investigators. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA, 2004, 291, 2319-2327.
10. Smith, P.K.; Shernan, S.K.; Chen, J.C.; Carrier, M.; Verrier, E.D.; Adams, P.X.; Todaro, T.G.; Muhlbaier, L.H.; Levy, J.H.; PRIMOCABG II Investigators. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials. J. Thorac. Cardiovasc. Surg., 2011, 142, 89-98.
11. APEX AMI Investigators; Armstrong, P.W.; Granger, C.B.; Adams, P.X.; Hamm, C.; Holmes, D. Jr.; O'Neill, W.W.; Todaro, T.G.; Vahanian, A.; Van de Werf, F. Pexelizumab for acute STelevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA, 2007, 297, 43-51.
12. Lin, G.M.; Chu, K.M.; Han, C.L. Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors. Int. J. Cardiol., 2011, 146, 280-282.
13. Røger, M.; Høgåsen, K.; Holme, P.A.; Halstensen, T.S.; Mollnes, T.E.; Hovig, T. The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood Platelets Inhibiting Platelets Aggregation. Platelet, 1995, 6, 160-168.
14. Lin, G.M.; Li, Y.H.; Wen, S.H.; Chen, S.Y.; Chu, K.M.; Han, C.L. Predictors, moderators and mediators for the effectiveness of pexelizumab treatment in patients undergoing primary coronary revascularization. Int. J. Cardiol., 2011, 147, 340-341.
15. Baron, R. M; Kenny, D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol., 1986, 51, 1173-1182.
16. Huber, K.; Holmes, D.R. Jr.; van't Hof, A.W.; Montalescot, G,.; Aylward, P.E.; Betriu, G.A.; Widimsky, P.; Westerhout, C.M.; Granger, C.B.; Armstrong, P.W. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur. Heart J., 2010, 31, 1708-1716.
17. Patel, M.R.; Worthley, S.G.; Stebbins, A.; Dill, T.; Rademakers, F.E.; Valeti, U.S.; Barsness, G.W.; Van de Werf, F.; Hamm, C.W.; Armstrong, P.W.; Granger, C.B.; Kim, R.J. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. JACC Cardiovasc Imaging., 2010, 3, 52-60.
18. Lin, G.M., Han, C.L. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur. Heart J., 2010, 31, 753-754.
19. Hermanides, R.S., Heestermans, A.A.; Ten Berg, J.M.; Gosselink, A.T.; Ottervanger, J.P.; van Houwelingen, K.G.; Kolkman, J.J.; Stella, P.R.; Dill, T., Hamm, C.; van't Hof, A.W. High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial. Heart, 2011, 97, 106-111.
20. Lin, G.M.; Li, Y.H.; Chu, K.M., Han, C.L. Controversies with On-TIME 2. Heart, 2011, 97, 1026.
21. Van't Hof, A.W.; Ten Berg, J.; Heestermans, T.; Dill, T; Funck, R.C.; van Werkum, W.; Dambrink, J.H.; Suryapranata, H.; van Houwelingen, G.; Ottervanger, J.P.; Stella, P; Giannitsis, E.; Hamm, C. Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomized controlled trial. Lancet, 2008, 372, 537-546.
22. Haverich, A.; Shernan, S.K.; Levy, J.H.; Chen, J.C.; Carrier, M.; Taylor, K.M.; Van de Werf, F.; Newman, M.F.; Adams, P.X.; Todaro, T.G.; van der Laan, M.; Verrier, E.D. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann. Thorac. Surg., 2006, 82, 486-492.
23. George, J.N.; Pickett, E.B.; Saucerman, S. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J. Clin. Invest., 1986, 78, 340-348.
24. Wenger, R.K.; Lukasiewicz, H.; Mikuta, B.S.; Niewiarowski, S.; Edmunds, L.H. Jr. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg., 1989, 97, 235-239.
25. Rinder, C.S.; Mathew, J.P.; Rinder, H.M.; Bonan, J.; Ault, K.A.; Smith, B.R. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology, 1991, 75, 563-70.
26. Lin, G.M.; Li, Y.H.; Han, C.L. A critical Appraisal of pexelizumab treatment in patients undergoing coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., 2011, 142, 472.